Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-I trial)

American Journal of Cardiology

Volumn 93, Issue 4, 2004, Pages 458-461

  Kandzari, David E ^b   Granger, Christopher B ^a   Simoons, Maarten L ^b   White, Harvey D ^b   Simes, John ^b   Mahaffey, Kenneth W ^b   Gore, Joel ^b   Weaver, W Douglas ^b   Longstreth Jr , William T ^b   Stebbins, Amanda ^b   Lee, Kerry L ^b   Califf, Robert M ^b   Topol, Eric J ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFECT; FACE INJURY; FEMALE; FIBRINOLYTIC THERAPY; HEAD INJURY; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME;

EID: 10744231754     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.10.043     Document Type: Article

References (4)

1. An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
2. Gore J.M., Granger C.B., Simoons M.L., Sloan M.A., Weaver W.D., White H.D., Barbash G.I., Van de Werf F., Aylward P.E., Topol E.J., Califf R.M. Stroke after thrombolysis mortality and functional outcomes in the GUSTO-I trial . Circulation. 92:1995;2811-2818.
3. Simoons M.L., Maggioni A.P., Knautterud G., Leimberger J.D., de Jaegere P., van Domburg R., Boersma E., Franzosi M.G., Califf R., Schroder R., et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet. 342:1993;1523-1528.
4. Simoons M.L., Arnold A.E.R. Tailored thrombolytic therapy a perspective . Circulation. 88:1993;2556-2564.